Keytruda for sarcoma – pro
SARC028 is a A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas, NCT02301039. Primary Outcome Measuresare Objective Response Rate.
Preliminary results showed a good response. The interim results from the phase II SARC028, multicenter clinical trial were reported at the Sarcoma Meeting at the Connective Tissue Oncology Society (CTOS) conference in Lisbon, Portugal.
Although the response rate was approximately 20% in the overall cohort of patients with soft tissue and bone sarcomas, a higher response of 44% was demonstrated in a subgroup of patients with undifferentiated pleomorphic sarcoma (UPS) who also experienced a reduction in tumor size.
The results have not been fully published and the approach is experimental, with the clinical trial continuing.
http://www.targetedonc.com/conference/ctos-2016/pembrolizumab-demonstrates-antitumor-activity-in-sarcoma-subtypes, Nov. 11, 2016
NCCN, Sfdt Tissue Sarcoma 2017
Keytruda, Perscribing Information 2017